polatuzumab vedotin + bendamustine + obinutuzumab

This therapy is a **three-drug combination** of polatuzumab vedotin, bendamustine, and obinutuzumab, used mainly for the treatment of relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). - **Polatuzumab vedotin** is an antibody-drug conjugate targeting CD79b on B-cells, delivering the microtubule inhibitor monomethyl auristatin E (MMAE) directly into malignant cells, inducing apoptosis via microtubule disruption. - **Obinutuzumab** is a type II glycoengineered anti-CD20 monoclonal antibody, causing B-cell lysis primarily through antibody-dependent cellular cytotoxicity (ADCC) and direct cell death. - **Bendamustine** is a cytotoxic small molecule, an alkylating agent that causes DNA cross-linking and apoptosis. The combination has shown clinical efficacy in phase Ib/II trials for relapsed/refractory FL and DLBCL. Approval for the triple-drug combination in these indications is not universal, but each component is individually approved, and the combination has been investigated in major clinical trials[1][3][5].

Other names

Pola-BGPola-Benda-Obinu